LONA — LeonaBio, Inc.
$4.84-2.62%
Last close: · regular session
After-hours $4.76 -1.67% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for LONA in the TickerWise workspace.
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 26
- Website: https://leonabio.com
Latest SEC filings for LONA
Latest LONA news
- ATHA Energy Successfully Completes Diamond Drilling at RIB North Discovery, Expanding Strike Length To 3.4 Km, And Identifies a Higher-Grade Sub Zone: Results Include RIBN-DD-023 Intersecting 19.5 M Of Composite Uranium Mineralization With 2.0 M Of High-Grade Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.